Geropharm looks to become leading insulin producer in Russia

Geropharm, one of Russia’s leading drugmakers, has officially commissioned a new plant for the production of insulin substances in St Petersburg, according to the company.

As an official spokesman of the company has said the new production is located in the Pushkin district of St Petersburg and is expected to be one of the largest of its kind in Russia. Its capacity at the initial stage will be 1 tonne of substances per year, with a possibility of expansion in due course, reports The Pharma Letter’s local correspondent.

The value of investments in the project amounted to 3.3 billion roubles (~$50 million). The plant is located on the area of more than 11,000 square meters. Future production will be supplied both to the local and foreign markets. The first stage of the plant was officially commissioned in September of 2017.